Table 3.
Comparison of demographic and disease characteristics of patients with hepatocellular carcinoma in both treatment groups
| Characteristic | TACE + sorafenib (n = 13) | TACE alone (n = 30) | P value |
| Age (yr) | 61.4 ± 7.5 | 59.2 ± 7.4 | 0.39 |
| Etiology | 0.18 | ||
| Alcohol | 2 (15.4) | 1 (3.4) | |
| Hepatitis C | 6 (46.1) | 17 (56.6) | |
| Hepatitis C and alcohol | 3 (23.1) | 11 (36.6) | |
| Non-alcohol/non-hepatitis C | 2 (15.4) | 1 (3.4) | |
| HCC histology | 0.86 | ||
| Poorly differentiated | 1 (7.6) | 3 (10.0) | |
| Moderately differentiated | 7 (53.8) | 13 (43.3) | |
| Well differentiated | 5 (38.6) | 14 (46.7) | |
| CTP classification | 0.69 | ||
| A | 11 | 23 | |
| B | 2 | 7 | |
| BCLC staging for HCC | 0.004 | ||
| A | 6 | 22 | |
| B | 2 | 8 | |
| C | 5 | 0 | |
| BCLC staging for HCC (excluding stage C) | 0.98 | ||
| A | 6 | 22 | |
| B | 2 | 8 | |
| MELD score | 8.8 ± 2.3 | 9.8 ± 2.9 | 0.29 |
| AFP (ng/mL) | 6.6 (2.3-745) | 8.1 (1.9-6000) | 0.96 |
| Tumor size seen on CT with the largest diameter (cm) | 4 (1.5 -16.7) | 3.1 (1.4 -5.8) | 0.58 |
Data are summarized as the mean ± SD or median (range). HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; CTP: Child-Turcotte-Pugh; BCLC: Barcelona Clinic Liver Cancer; MELD: Model of end stage liver disease; AFP: Alpha fetoprotein; CT: Computed tomography.